1 |
Antonia, S., J. J. Mule, and S. Weber (2004), Current developments of immunotherapy in the clinic, Curr. Opin. Immunol. 16, 1-7
|
2 |
Pulendran, B., K. Palucka, and J. Banchereau (2001), Sensing pathogenes and tuning immune responses, Science 293(5528), 253-256
|
3 |
Jefford, M., E. maraskovsky, J. Cebon, and I. D. Davis (2001), The use of dendritic cells in cancer therapy. Lancet Oncol. 2, 343-353
|
4 |
Hwang, J. W., M. Kim, K. Kim (1998), T cell epitope analysis of structural protein of adenovirus, Kor. J. Immunol. 20(4), 435-442
|
5 |
Kjaergaard, J., K. Shimizu, and S. Shu (2003), Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine, Cell. Immunol. 255, 65-74
|
6 |
Thumann, P. I. Moc and L. Jenne et al. (2003), Antigen loading of dendritic cells with whole tumor cell preparations, J. Immunol. Methods 277, 1-16
|
7 |
Ruffini, P. A. and L. W. Kwak (2001), Immunotheraphy of multiple myeloma, Semin. Hematol. 38, 260-267
|
8 |
Bella, S. D. et al. (2003), Altered maturation of peripheral blood dendritic cells in patients with breast cancer, Br. J. cancer. 89, 1463-1472
|
9 |
Krueger, C. et al. (2004), Quality and quantity: new strategies to improve immunotherapy of cancer, TRENDS in Mol. Med. 10(5), 205-208
|
10 |
Wick, M. et al. (1997), Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy, J. Exp. Med. 186(2), 229-238
|
11 |
Steinman, R. M. and M. Pope (2002), Exploiting dendritic cells to improve vaccine efficacy, J. Clin. Invest. 109(12), 1519-1526
|
12 |
Jung, S. (2004), Good, Bed and beautiful-the role of dendritic cells in autoimmunity, Autoimmunity Rev. 3, 54-60
|
13 |
Martins, M. T. and A. L. Witzel, et al. (2004), Dendritic cell sarcoma of the oral cavity, Oral. Oncol. 40, 341-347
|
14 |
Nastle, F. O., S. Alijagic, and M. Gilliet et al. (1998), Vaccination of melanoma patients with peptide- or tumor-lysate plused dendritic cells, Nat. Med. 4, 328-332
|
15 |
Bae, J. M. and J. P. Kim (1998), Effect of adjuvant immunochemotherapy on immunologic function of gastric cancer patients, Kor. Sur. Society 55(2), 190-197
|
16 |
Banchereau. J. and R. M. Steinman (1998), Dendritic cells and the control of immunity, Nature 392, 245-252
|
17 |
Yan, X., B. D. Johnson, and R. J. Orentas (2004), Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expression on neuroblastoma expands CD8 tumor-reactive effector cells in vivo, Immunology 112(1), 105-116
|
18 |
May, K. F., Jr., L. Chen, P. Zheng, and Y. Lui (2002), Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by priming survival but not clonal expansion of tumor-specific CD8+ T cells, Cancer Res. 62, 3459-3465
|
19 |
Banchereau, J., R. M. Steinman (1998), Dendritic cells and the control of immunity, Nature 392, 245-252
|
20 |
Dallal, R. M. and M. T. Lotze (2000), The dendritic cell and human cancer vaccines, Curr. Opin. Immunol. 12, 583-588
|
21 |
Bozza, S. and L. Romani et al. (2004), Dendritic cell-based vaccination against opportunistic fungi, Vaccine 22, 857-864
|
22 |
Finn, O. J. (2004), Tumor immunology Tumor immunology at the service of cancer immunotherapy, Curr. Opin. Immunol. 16, 1-3
|
23 |
Boon, T. and B. V. Eynde (2003), Tumor Immunology, Curr. Opin. Immunol. 15, 129-130
|
24 |
Belli, F. et al. (2002), Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings, J. Clin. Oncol. 20(20), 4169-4180
|
25 |
Hsueh, E. C., R. K. Gupta, K. Qi, D. L. Morton (1998), Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine, J. Clin. Oncol. 16, 2913-2920
|
26 |
Yuji, T., T. Masatoshi et al. (2003), T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines, Cancer Gene Ther. 10, 451-456
|
27 |
Maus, M. V., J. L. Riley, and C. H. June et al. (2003), HLA teramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells, Clin. Immunol. 106, 16-22
|
28 |
Orchard, P. J. et al. (2002), Clinical-scale selection of anti-CD3 /CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor, Hum. Gene Ther. 13(8), 979-988
|
29 |
International Agency for Research on Cancer-WHO. Cancer research for cancer control. IARC, Lyon, France, 2001
|
30 |
Suh, H. S. and M. D. (1993), The Role of Radiation Therapy in Cancer Management, Inje. Med. J. 4(3), 253-258
|
31 |
Singh, M. and D. O'Hagan (1999), Advances in vaccine adjuvants, Nat. Biotechnol. 17, 1075-1081
|
32 |
Schijins, V. E. (2000), Immunological concepts of vaccine adjuvant activity, Curr. Opin. Immunol. 12, 456-463
|
33 |
Yoo, K. Y. and H. R. Shin (2003), Cancer Epidemiology and Prevention, Kor. J. Epidem. 25(1), 1-15
|
34 |
O'Doherty, U. et al. (1994), Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature, Immunology 82, 878-884
|
35 |
Oleike, M. et al. (2003), Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells, Nature 9(5), 619-625
|
36 |
Enk, A. H., H. Jonuleit, J. Saloga, and J. Knop (1997), Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma, Int. J. Cancer. 73(3), 309-316
|
37 |
Lee, P. P. et al. (1999), Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Med. 5, 677-685
|
38 |
Terabe, M. and J. A. Berzofsky (2004), Immunoregulatory T cells in Tumor Immunity, Curr. Opin. Immunol. 16, 1-6
|
39 |
Gunzer, M. et al. (2001), Dendritic cells and tumor immunity immunology, Immunology 13, 291-302
|
40 |
Carbone, F. R. and W. R. Heath (2003), The role of dendritic cell subsets in immunity to virus, Curr. Opin. Immunol. 15, 416-420
|
41 |
Ratta, M. et al. (2002), Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6, Blood 100, 230-237
|
42 |
Knuth, A., T. Wolfel, and E. Klemann et al. (1989), Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection, Proc. Natl. Acad. Sci. USA 86(8), 2804-2808
|
43 |
Soiffer, R. et al. (2003), Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma, J. Clin. Oncol. 21(17), 3343-3350
|
44 |
Finn, O. J. (2003), Cancer vaccines: between the idea and the reality, Nat. Rev. Immunol. 3(8), 630-641
|
45 |
Sadanaga, N. et al. (2001), Dendritic cell vaccination with MAGE peptides is a novel therapeutic approach for gastrointestinal carcinomas, Clin. Cancer. Res. 7, 2277-2284
|